Literature DB >> 21168185

Coagulation and autoimmunity in scleroderma interstitial lung disease.

Anna Ludwicka-Bradley1, Richard M Silver, Galina S Bogatkevich.   

Abstract

OBJECTIVES: Interstitial lung disease in systemic sclerosis (SSc-ILD) is often an irreversible and progressive fibrosing process that now is the leading cause of scleroderma-related deaths. In this review we present our current understanding of the role played by coagulation and particularly by thrombin in autoimmune-mediated tissue injury and fibrosis, mainly as it relates to SSc-ILD.
METHODS: We used PubMed to search for articles published up to October 2010 for keywords referring to autoimmunity, coagulation, pulmonary fibrosis, and scleroderma.
RESULTS: SSc-ILD is an autoimmune disease associated with lymphocyte activation and release of various cytokines and growth factors. The production of autoantibodies is a central feature in SSc. Activation of the coagulation cascade with release of thrombin is 1 of the earliest events following tissue injury. Thrombin contributes to autoimmune responses by activating of pathogenic Th2 lymphocyte profile in SSc. Thrombin also modulates tissue repair responses, stimulates transformation of epithelial cells, endothelial cells, and fibroblasts into myofibroblast phenotype, and induces secretion of several pro-immune and profibrotic factors, which serve as antigens for pathogenic autoantibodies production in SSc-ILD.
CONCLUSIONS: The identification of links between autoimmunity and coagulation would provide new insights into the pathogenesis of pulmonary fibrosis associated with autoimmune diseases and further acknowledge the importance of thrombin in the development of SSc-ILD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21168185      PMCID: PMC3072434          DOI: 10.1016/j.semarthrit.2010.10.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  105 in total

Review 1.  Regulation of matrix biology by matrix metalloproteinases.

Authors:  Joni D Mott; Zena Werb
Journal:  Curr Opin Cell Biol       Date:  2004-10       Impact factor: 8.382

2.  The perforin mediated apoptotic pathway in lung injury and fibrosis.

Authors:  H Miyazaki; K Kuwano; K Yoshida; T Maeyama; M Yoshimi; M Fujita; N Hagimoto; R Yoshida; Y Nakanishi
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

3.  Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment.

Authors:  A Pignone; C Scaletti; M Matucci-Cerinic; D Vázquez-Abad; P L Meroni; N Del Papa; F Falcini; S Generini; N Rothfield; M Cagnoni
Journal:  Clin Exp Rheumatol       Date:  1998 Sep-Oct       Impact factor: 4.473

4.  Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma.

Authors:  S Gay; R E Jones; G Q Huang; R E Gay
Journal:  J Invest Dermatol       Date:  1989-02       Impact factor: 8.551

Review 5.  The role of protease activation of inflammation in allergic respiratory diseases.

Authors:  Charles E Reed; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2004-11       Impact factor: 10.793

6.  Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.

Authors:  C Nishijima; I Hayakawa; T Matsushita; K Komura; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

Review 7.  Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.

Authors:  Shinichi Sato; Manabu Fujimoto; Minoru Hasegawa; Kazuhiko Takehara; Thomas F Tedder
Journal:  Mol Immunol       Date:  2004-11       Impact factor: 4.407

8.  Differentiation of human NK cells into NK1 and NK2 subsets.

Authors:  D Peritt; S Robertson; G Gri; L Showe; M Aste-Amezaga; G Trinchieri
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

9.  Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis.

Authors:  M Hasegawa; S Sato; K Yanaba; K Komura; M Yamazaki; K Takehara
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

10.  Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor.

Authors:  T Ohba; J K McDonald; R M Silver; C Strange; E C LeRoy; A Ludwicka
Journal:  Am J Respir Cell Mol Biol       Date:  1994-04       Impact factor: 6.914

View more
  10 in total

Review 1.  An update on the evaluation and management of pulmonary hypertension in scleroderma.

Authors:  John G Coghlan; Benjamin Schreiber; Benjamin Schrieber
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 2.  Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Ivan O Rosas; Paul F Dellaripa; David J Lederer; Dinesh Khanna; Lisa R Young; Fernando J Martinez
Journal:  Ann Am Thorac Soc       Date:  2014-04

3.  Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population-Based Study.

Authors:  Sara R Schoenfeld; Hyon K Choi; Eric C Sayre; J Antonio Aviña-Zubieta
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-02       Impact factor: 4.794

4.  Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.

Authors:  Gyu-Tae Park; Jung-Won Yoon; Sang-Bin Yoo; Young-Chul Song; Parkyong Song; Hyoung-Kyu Kim; Jin Han; Sung-Jin Bae; Ki-Tae Ha; Natalia P Mishchenko; Sergey A Fedoreyev; Valentin A Stonik; Moon-Bum Kim; Jae-Ho Kim
Journal:  Mar Drugs       Date:  2021-04-23       Impact factor: 5.118

5.  Identifying common genes and networks in multi-organ fibrosis.

Authors:  Kevin E Wenzke; Carmen Cantemir-Stone; Jie Zhang; Clay B Marsh; Kun Huang
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2012-03-19

6.  A methodology for exploring biomarker--phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations.

Authors:  Hongtai Huang; Andrea Fava; Tara Guhr; Raffaello Cimbro; Antony Rosen; Francesco Boin; Hugh Ellis
Journal:  BMC Bioinformatics       Date:  2015-09-15       Impact factor: 3.169

Review 7.  The molecular virology of coronaviruses.

Authors:  Ella Hartenian; Divya Nandakumar; Azra Lari; Michael Ly; Jessica M Tucker; Britt A Glaunsinger
Journal:  J Biol Chem       Date:  2020-07-13       Impact factor: 5.157

8.  Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease.

Authors:  R M Silver; D A Wilson; T Akter; I Atanelishvili; J T Huggins; K Kajdasz; K B Highland; P J Nietert; G S Bogatkevich
Journal:  ACR Open Rheumatol       Date:  2019-08-06

Review 9.  An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.

Authors:  Corrado Campochiaro; Yannick Allanore
Journal:  Arthritis Res Ther       Date:  2021-06-01       Impact factor: 5.156

Review 10.  Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases.

Authors:  Margaret Markiewicz; Erin Richard; Natalia Marks; Anna Ludwicka-Bradley
Journal:  J Aging Res       Date:  2013-10-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.